{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:52:39Z","timestamp":1792000359985,"version":"4.4.0"},"reference-count":63,"publisher":"American Veterinary Medical Association (AVMA)","issue":"S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in dogs. Many studies and case reports have been published in the past 10 years on the efficacy and safety of this medication, both at labeled doses to treat allergic dogs and off label to treat other diseases and given to other species. Concerns and confusion have occurred for both clinicians and owners regarding the long-term safety of this drug. The purpose of this review is to present the current knowledge on the efficacy, speed of action, effects on the immune system, and clinical safety of oclacitinib, based on evidence and published literature. We also aim to summarize the lessons learned in the past 10 years and to propose directions for the future.<\/jats:p>","DOI":"10.2460\/javma.22.12.0570","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:39:15Z","timestamp":1679387955000},"page":"S36-S47","source":"Crossref","is-referenced-by-count":42,"title":["Oclacitinib 10 years later: lessons learned and directions for the future"],"prefix":"10.2460","volume":"261","author":[{"given":"Rosanna","family":"Marsella","sequence":"first","affiliation":[{"name":"University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Doerr","sequence":"additional","affiliation":[{"name":"Maitland, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gonzales","sequence":"additional","affiliation":[{"name":"Zoetis Global Therapeutics Research, Kalamazoo, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Rosenkrantz","sequence":"additional","affiliation":[{"name":"Animal Dermatology Clinic, Tustin, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schissler","sequence":"additional","affiliation":[{"name":"Zoetis Petcare Veterinary Professional Services, Parsippany, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"White","sequence":"additional","affiliation":[{"name":"Auburn University College of Veterinary Medicine and Clinical Sciences, Auburn, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"4","key":"B1","series-title":"J Vet Pharmacol Ther","first-page":"317","article-title":"Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales AJ","year":"2014","unstructured":"Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317\u2013324. doi:10.1111\/jvp.1210124495176"},{"issue":"3","key":"B2","series-title":"J Vet Pharmacol Ther","first-page":"279","article-title":"The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog","volume":"37","author":"Collard WT","year":"2014","unstructured":"Collard WT, Hummel BD, Fielder AF, et al. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J Vet Pharmacol Ther. 2014;37(3):279\u2013285. doi:10.1111\/jvp.1208724330031"},{"issue":"5","key":"B3","series-title":"Vet Dermatol","first-page":"470-e114","article-title":"Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis","volume":"24","author":"Cosgrove SB","year":"2013","unstructured":"Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):470-e114. doi:10.1111\/vde.12047"},{"issue":"1","key":"B4","series-title":"Vet Dermatol","first-page":"17-e6.5","article-title":"Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production","volume":"30","author":"Banovic F","year":"2018","unstructured":"Banovic F, Tarigo J, Gordon H, Barber JP, Gogal RM Jr. Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production. Vet Dermatol. 2018;30(1):17-e6.5. doi:10.1111\/vde.12698"},{"key":"B5","series-title":"Res Vet Sci","first-page":"124","article-title":"Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro","volume":"121","author":"Jasiecka-Miko\u0142ajczyk A","year":"2018","unstructured":"Jasiecka-Miko\u0142ajczyk A, Jaroszewski JJ, Ma\u015blanka T. Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro. Res Vet Sci. 2018;121:124\u2013129. doi:10.1016\/j.rvsc.2018.10.01430391724"},{"issue":"18","key":"B6","series-title":"Molecules","first-page":"5655","article-title":"Oclacitinib, a janus kinase inhibitor, reduces the frequency of IL-4- and IL-10-, but not IFN-\u03b3-, producing murine CD4+ and CD8+ T cells and counteracts the induction of type 1 regulatory T cells","volume":"26","author":"Jasiecka-Miko\u0142ajczyk A","year":"2021","unstructured":"Jasiecka-Miko\u0142ajczyk A, Jaroszewski JJ, Ma\u015blanka T. Oclacitinib, a janus kinase inhibitor, reduces the frequency of IL-4- and IL-10-, but not IFN-\u03b3-, producing murine CD4+ and CD8+ T cells and counteracts the induction of type 1 regulatory T cells. Molecules. 2021;26(18):5655. doi:10.3390\/molecules26185655"},{"key":"B7","series-title":"Vet Dermatol","first-page":"389","article-title":"Oclacitinib (Apoquel) inhibits allergen-induced production of interleukin-31 but not interferon-gamma or interleukin-4 in canine Th2 cells","volume":"25","author":"Rugg CA","year":"2014","unstructured":"Rugg CA, Mccandless EE, Messamore JE, Gonzales AJ. Oclacitinib (Apoquel) inhibits allergen-induced production of interleukin-31 but not interferon-gamma or interleukin-4 in canine Th2 cells. Vet Dermatol. 2014;25:389."},{"key":"B8","series-title":"Vet Dermatol","article-title":"Long-term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T-cells, IL-10 and TGF-\u03b2, in dogs with atopic dermatitis","author":"Herrmann I","year":"In press","unstructured":"Herrmann I, Mamo LB, Holmes J, Mohammed JP, Murphy KM, Bizikova P. Long-term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T-cells, IL-10 and TGF-\u03b2, in dogs with atopic dermatitis. Vet Dermatol. In press. doi:10.1111\/vde.13140"},{"key":"B9","series-title":"BMC Vet Res","first-page":"196","article-title":"Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification","volume":"11","author":"Hensel P","year":"2015","unstructured":"Hensel P, Santoro D, Favrot C, Hill P, Griffin C. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC Vet Res. 2015;11:196. doi:10.1186\/s12917-015-0515-526260508"},{"issue":"3","key":"B10","series-title":"Vet Dermatol","first-page":"171-e35","article-title":"Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life","volume":"26","author":"Cosgrove SB","year":"2015","unstructured":"Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-e35. doi:10.1111\/vde.12194"},{"issue":"1","key":"B11","series-title":"Vet Dermatol","first-page":"23-e8","article-title":"A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs","volume":"26","author":"Little PR","year":"2015","unstructured":"Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-e8. doi:10.1111\/vde.12186"},{"issue":"6","key":"B12","series-title":"Vet Dermatol","first-page":"512-e86","article-title":"Efficacy of oclacitinib (Apoquel\u00ae) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia","volume":"25","author":"Gadeyne C","year":"2014","unstructured":"Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel\u00ae) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-e86. doi:10.1111\/vde.12166"},{"issue":"2","key":"B13","series-title":"Vet Dermatol","first-page":"149-e42","article-title":"Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs","volume":"33","author":"Denti D","year":"2022","unstructured":"Denti D, Caldin M, Ventura L, De Lucia M. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs Vet Dermatol. 2022;33(2):149-e42. doi:10.1111\/vde.1305335014745"},{"issue":"6","key":"B14","series-title":"Vet Dermatol","first-page":"587-e142","article-title":"A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel\u00ae) in client-owned dogs with atopic dermatitis","volume":"24","author":"Cosgrove SB","year":"2013","unstructured":"Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel\u00ae) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24:(6):587-e142. doi:10.1111\/vde.12088"},{"issue":"1","key":"B15","series-title":"Vet Dermatol","first-page":"34-e10","article-title":"IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics","volume":"27","author":"Gonzales AJ","year":"2016","unstructured":"Gonzales AJ, Fleck TJ, Humphrey WR, et al. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics. Vet Dermatol. 2016;27(1):34-e10. doi:10.1111\/vde.1228026666963"},{"issue":"6","key":"B16","series-title":"Vet Dermatol","first-page":"489-e164","article-title":"A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA","volume":"29","author":"Souza CP","year":"2018","unstructured":"Souza CP, Rosychuk RAW, Contreras ET, Schissler JR, Simpson AC. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol. 2018;29(6):489-e164. doi:10.1111\/vde.12682"},{"issue":"6","key":"B17","series-title":"Vet Dermatol","first-page":"505-e136","article-title":"A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis","volume":"27","author":"Michels GM","year":"2016","unstructured":"Michels GM, Walsh KF, Kryda KA, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol. 2016;27(6):505-e136. doi:10.1111\/vde.1236427647513"},{"issue":"4","key":"B18","series-title":"Vet Dermatol","first-page":"284-e69","article-title":"Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs","volume":"31","author":"Marsella R","year":"2020","unstructured":"Marsella R, Ahrens K, Wilkes R, Trujillo A, Dorr M. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs. Vet Dermatol. 2020;31(4):284-e69. doi:10.1111\/vde.12849"},{"issue":"7","key":"B19","series-title":"Int J Vet Health Sci Res","first-page":"208","article-title":"Efficacy of Apoquel for the control of otitis externa secondary to allergic skin disease in client-owner dogs","volume":"5","author":"Gotthelf LN","year":"2017","unstructured":"Gotthelf LN. Efficacy of Apoquel for the control of otitis externa secondary to allergic skin disease in client-owner dogs. Int J Vet Health Sci Res. 2017;5(7):208\u2013212."},{"key":"B20","unstructured":"US Food and Drug Administration. Apoquel FOI. Accessed December 1, 2022. http:\/\/www.fda.gov\/downloads\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/FOIADrugSummaries\/UCM363901.pdf"},{"issue":"5","key":"B21","series-title":"J Am Vet Med Assoc","first-page":"507","article-title":"Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib","volume":"257","author":"Lancellotti B","year":"2020","unstructured":"Lancellotti B, Angus J, Edginton H, Rosenkrantz WS. Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib. J Am Vet Med Assoc. 2020;257(5):507\u2013516. doi:10.2460\/javma.257.5.50732808904"},{"issue":"5","key":"B22","series-title":"Vet Dermatol","first-page":"485-e113","article-title":"The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study","volume":"28","author":"Simpson A","year":"2017","unstructured":"Simpson A, Schissler J, Rosychuk R, Moore R. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study. Vet Dermatol. 2017;28(5):485-e113. doi:10.1111\/vde.1245028513001"},{"key":"B23","article-title":"Apoquel\u00ae film-coated tablets for dogs","year":"2018","unstructured":"Zoetis. Apoquel\u00ae film-coated tablets for dogs. Zoetis Belgium SA; 2018."},{"key":"B24","series-title":"Front Vet Sci","first-page":"631443","article-title":"The association between the use of oclacitinib and antibacterial therapy in dogs with allergic dermatitis: a retrospective case-control study","volume":"8","author":"Rynhoud H","year":"2021","unstructured":"Rynhoud H, Gibson JS, Meler E, Soares Magalh\u00e3es RJ. The association between the use of oclacitinib and antibacterial therapy in dogs with allergic dermatitis: a retrospective case-control study. Front Vet Sci. 2021;8:631443. doi:10.3389\/fvets.2021.63144333681331"},{"issue":"5","key":"B25","series-title":"Vet Dermatol","first-page":"439-e146","article-title":"A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs","volume":"29","author":"Marsella R","year":"2018","unstructured":"Marsella R, Ahrens K. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs. Vet Dermatol. 2018;29(5):439-e146. doi:10.1111\/vde.12660"},{"issue":"1","key":"B26","series-title":"BMC Dermatol","first-page":"15","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp KA","year":"2016","unstructured":"Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol. 2016;16(1):15. doi:10.1186\/s12895-016-0051-427716172"},{"issue":"1","key":"B27","series-title":"Rheum Dis Clin North Am","first-page":"79","article-title":"Malignancy and Janus kinase inhibition","volume":"43","author":"Sivaraman P","year":"2017","unstructured":"Sivaraman P, Cohen SB. Malignancy and Janus kinase inhibition. Rheum Dis Clin North Am. 2017;43(1):79\u201393. doi:10.1016\/j.rdc.2016.09.00827890175"},{"issue":"8","key":"B28","series-title":"Leukemia","first-page":"1701","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison CN","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701\u20131707. doi:10.1038\/leu.2016.14827211272"},{"key":"B29","article-title":"Oclacitinib (Apoquel)","year":"2020","unstructured":"Zoetis. Oclacitinib (Apoquel). Zoetis Inc; 2020."},{"issue":"1","key":"B30","series-title":"Acta Vet Scand","first-page":"6","article-title":"Mast cell tumors and other skin neoplasia in Danish dogs\u2013data from the Danish Veterinary Cancer Registry","volume":"52","author":"Bronden LB","year":"2010","unstructured":"Bronden LB, Eriksen T, Kristensen AT. Mast cell tumors and other skin neoplasia in Danish dogs\u2013data from the Danish Veterinary Cancer Registry. Acta Vet Scand. 2010;52(1):6. doi:10.1186\/1751-0147-52-6"},{"issue":"2","key":"B31","series-title":"Vet Dermatol","first-page":"159-e46","article-title":"Cytokine production and the effects of oclacitinib in three canine mast cell tumour lines","volume":"33","author":"De Mello Souza CH","year":"2021","unstructured":"De Mello Souza CH, Shiomitsu K, Hwang B. Cytokine production and the effects of oclacitinib in three canine mast cell tumour lines. Vet Dermatol. 33(2):159-e46, 2021. doi:10.1111\/vde.1304634882871"},{"issue":"2","key":"B32","series-title":"Vet Dermatol","first-page":"101","article-title":"Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: a retrospective case-control study","volume":"18","author":"Santoro D","year":"2007","unstructured":"Santoro D, Marsella R, Hernandez J. Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: a retrospective case-control study. Vet Dermatol. 2007;18(2):101\u2013106. doi:10.1111\/j.1365-3164.2007.00582.x17355424"},{"key":"B33","series-title":"Vet Dermatol","first-page":"426","article-title":"A retrospective study comparing the incidence of cutaneous histiocytoma development in atopic dogs treated with oclacitinib and ciclosporin. Abstracts of the North American Veterinary Dermatology Forum 26\u201329 April 2017 Orlando, FL, USA","volume":"28","author":"High EJ","year":"2017","unstructured":"High EJ, Lam A, Ferrer L. A retrospective study comparing the incidence of cutaneous histiocytoma development in atopic dogs treated with oclacitinib and ciclosporin. Abstracts of the North American Veterinary Dermatology Forum 26\u201329 April 2017 Orlando, FL, USA. Vet Dermatol. 2017;28:426\u2013455. doi:10.1111\/vde.12452"},{"issue":"2","key":"B34","series-title":"Vet Dermatol","first-page":"110-e30","article-title":"A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with non-flea nonfood-induced hypersensitivity dermatitis","volume":"30","author":"Noli C","year":"2019","unstructured":"Noli C, Matricoti I, Schievano C. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with non-flea nonfood-induced hypersensitivity dermatitis. Vet Dermatol. 2019;30(2):110-e30. doi:10.1111\/vde.12720"},{"issue":"1","key":"B35","series-title":"BMC Vet Res","first-page":"137","article-title":"A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats","volume":"15","author":"Lopes NL","year":"2019","unstructured":"Lopes NL, Campos DR, Machado MA, et al. A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats. BMC Vet Res. 2019;15(1):137. doi:10.1186\/s12917-019-1893-x31068210"},{"issue":"4","key":"B36","series-title":"Vet Dermatol","first-page":"235-e53","article-title":"Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats","volume":"26","author":"Ortalda C","year":"2015","unstructured":"Ortalda C, Noli C, Colombo S, Borio S. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. Vet Dermatol. 2015;26(4):235-e53. doi:10.1111\/vde.12218"},{"issue":"8","key":"B37","series-title":"J Feline Med Surg","first-page":"787","article-title":"Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response","volume":"24","author":"Carrasco I","year":"2022","unstructured":"Carrasco I, Ferrer L, Puigdemont A. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. J Feline Med Surg. 2022;24(8):787\u2013793. doi:10.1177\/1098612X21104845834612749"},{"issue":"2","key":"B38","series-title":"Vet Dermatol","first-page":"134","article-title":"A pharmacokinetic study of oclacitinib maleate in six cats","volume":"31","author":"Ferrer L","year":"2020","unstructured":"Ferrer L, Carrasco I, Cristofol C, Puigdemont A. A pharmacokinetic study of oclacitinib maleate in six cats. Vet Dermatol. 2020;31(2):134\u2013137. doi:10.1111\/vde.1281931769185"},{"key":"B39","series-title":"Aust Vet Pract","first-page":"159","article-title":"Reactivated toxoplasmosis in a FIV-positive cat","volume":"28","author":"Foster SF","year":"1998","unstructured":"Foster SF, Charles JA, Canfield PJ, Beatty JA, Martin P. Reactivated toxoplasmosis in a FIV-positive cat. Aust Vet Pract. 1998;28:159\u2013163."},{"key":"B40","series-title":"J Vet Int Med","first-page":"2979","article-title":"Pharmacokinetics of oclacitinib following oral and intravenous administration to horses. 2020 ACVIM Forum on Demand Research Abstract Program","volume":"34","author":"Collard W","year":"2020","unstructured":"Collard W, Thorn J, Smith S, et al. Pharmacokinetics of oclacitinib following oral and intravenous administration to horses. 2020 ACVIM Forum on Demand Research Abstract Program. J Vet Int Med. 2020;34:2979."},{"issue":"5","key":"B41","series-title":"Vet Dermatol","first-page":"435","article-title":"Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome","volume":"33","author":"Moore A","year":"2022","unstructured":"Moore A, Burrows A, Malik R, Ghubash RM, Last RD, Remaj B. Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome. Vet Dermatol. 2022;33(5):435\u2013439. doi:10.1111\/vde.13097"},{"issue":"1\u22122","key":"B42","series-title":"Aust Vet J","first-page":"30","article-title":"Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy","volume":"84","author":"Barrs VR","year":"2006","unstructured":"Barrs VR, Martin P, Beatty JA. Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy. Aust Vet J. 2006;84(1\u22122):30\u201335. doi:10.1111\/j.1751-0813.2006.tb13119.x16498831"},{"issue":"4","key":"B43","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"472","article-title":"Acute respiratory distress syndrome and septic shock in a cat with disseminated toxoplasmosis","volume":"27","author":"Evans NA","year":"2017","unstructured":"Evans NA, Walker JM, Manchester A, Bach JF. Acute respiratory distress syndrome and septic shock in a cat with disseminated toxoplasmosis. J Vet Emerg Crit Care (San Antonio). 2017;27(4):472\u2013478. doi:10.1111\/vec.12621"},{"issue":"3","key":"B44","series-title":"Vet Dermatol","first-page":"194","article-title":"A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin for feline atopy","volume":"15","author":"Last RD","year":"2004","unstructured":"Last RD, Suzuki Y, Manning T, Lindsay D, Galipeau L, Whitbread T. A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin for feline atopy. Vet Dermatol. 2004;15(3):194\u2013198. doi:10.1111\/j.1365-3164.2004.00371.x"},{"issue":"3","key":"B45","series-title":"J Vet Pharmacol Ther","first-page":"320","article-title":"Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses","volume":"45","author":"Hunyadi L","year":"2022","unstructured":"Hunyadi L, Datta P, Rewers-Felkins K, et al. Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses. J Vet Pharmacol Ther. 2022;45(3):320\u2013324. doi:10.1111\/jvp.1304335098559"},{"key":"B46","series-title":"J Vet Int Med","first-page":"2977","article-title":"Oclacitinib maleate (Apoquel) dose determination in horses with naturally occurring allergic dermatitis. 2020 ACVIM Forum on Demand Research Abstract Program","volume":"34","author":"Visser M","year":"2020","unstructured":"Visser M, Cleaver D, Cundiff B, King V, Sture G. Oclacitinib maleate (Apoquel) dose determination in horses with naturally occurring allergic dermatitis. 2020 ACVIM Forum on Demand Research Abstract Program. J Vet Int Med. 2020;34:2977\u20132978."},{"issue":"3","key":"B47","series-title":"Vet Dermatol","first-page":"201-e63","article-title":"The role of oclacitinib in the management of ischaemic dermatopathy in four dogs","volume":"30","author":"Levy BJ","year":"2019","unstructured":"Levy BJ, Linder KE, Olivry T. The role of oclacitinib in the management of ischaemic dermatopathy in four dogs. Vet Dermatol. 2019;30(3):201-e63. doi:10.1111\/vde.1274331006925"},{"key":"B48","series-title":"Vet Dermatol","first-page":"371","article-title":"Juvenile-onset ischaemic dermatopathy in two dogs treated with oclacitinib. Abstracts of the 30th Annual Congress of the ECVD-ESVD, 2018, Dubrovnik, Croatia","volume":"29","author":"Pulsoni D","year":"2018","unstructured":"Pulsoni D, Friere A, Ferreira R. Juvenile-onset ischaemic dermatopathy in two dogs treated with oclacitinib. Abstracts of the 30th Annual Congress of the ECVD-ESVD, 2018, Dubrovnik, Croatia. Vet Dermatol. 2018;29:371."},{"key":"B49","series-title":"Acta Sci Vet","article-title":"Juvenile-onset ischemic dermatopathy in a dog","volume":"49","author":"Cousandier G","year":"2021","unstructured":"Cousandier G, Scholten AD, Scotton G, Stefanello C. Juvenile-onset ischemic dermatopathy in a dog. Acta Sci Vet. 2021;49. doi:10.22456\/1679-9216.105583"},{"issue":"5","key":"B50","series-title":"Vet Dermatol","first-page":"512-e123","article-title":"A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib","volume":"28","author":"Aymeric E","year":"2017","unstructured":"Aymeric E, Bensignor E. A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib. Vet Dermatol. 2017;28(5):512-e123. doi:10.1111\/vde.1245828635010"},{"issue":"3","key":"B51","series-title":"Vet Dermatol","first-page":"237-e65","article-title":"A case report of the beneficial effect of oclacitinib in a dog with pemphigus vulgaris","volume":"33","author":"Martinez N","year":"2022","unstructured":"Martinez N, McDonald B, Crowley A. A case report of the beneficial effect of oclacitinib in a dog with pemphigus vulgaris. Vet Dermatol. 2022;33(3):237-e65. doi:10.1111\/vde.13063"},{"issue":"4","key":"B52","series-title":"Vet Dermatol","first-page":"363-e100","article-title":"Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series","volume":"32","author":"Colombo S","year":"2021","unstructured":"Colombo S, Cornegliani L, Vercelli A, Fondati A. Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series. Vet Dermatol. 2021;32(4):363-e100. doi:10.1111\/vde.1299234250688"},{"issue":"4","key":"B53","series-title":"Vet Dermatol","first-page":"330-e86","article-title":"Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs","volume":"31","author":"High EJ","year":"2020","unstructured":"High EJ, Linder KE, Mamo LB, Levy BJ, Herrmann I, Bizikova P. Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs. Vet Dermatol. 2020;31(4):330-e86. doi:10.1111\/vde.1285232307815"},{"issue":"3","key":"B54","series-title":"Vet Sci","first-page":"127","article-title":"Inherited sensory and autonomic neuropathy in a border collie, interest of oclacitinib for the control of self-mutilation","volume":"9","author":"Leonard C","year":"2022","unstructured":"Leonard C, Van Soens I, Fontaine J. Inherited sensory and autonomic neuropathy in a border collie, interest of oclacitinib for the control of self-mutilation. Vet Sci. 2022;9(3):127. doi:10.3390\/vetsci9030127"},{"key":"B55","series-title":"Vet Dermatol","first-page":"277","article-title":"Assessment of oclacitinib as a treatment for canine chronic idiopathic rhinitis using a validated rhinitis scoring instrument: a retrospective study. Abstracts of the 2019 North American Veterinary Dermatology Forum","volume":"30","author":"Anderson T","year":"2019","unstructured":"Anderson T, Schissler J. Assessment of oclacitinib as a treatment for canine chronic idiopathic rhinitis using a validated rhinitis scoring instrument: a retrospective study. Abstracts of the 2019 North American Veterinary Dermatology Forum. Vet Dermatol. 2019;30:277\u2013306. doi:10.1111\/vde.12750"},{"issue":"5","key":"B56","series-title":"Vet Ophthalmol","first-page":"633","article-title":"Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca","volume":"22","author":"de Oliveira JK","year":"2019","unstructured":"de Oliveira JK, Williams DL, Bollmann C, de Seabra NM, Bortolini M, Montiani-Ferreira F. Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca. Vet Ophthalmol. 2019;22(5):633\u2013643. doi:10.1111\/vop.1263430724448"},{"issue":"3","key":"B57","series-title":"Vet Dermatol","first-page":"299","article-title":"Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus","volume":"32","author":"Carrasco I","year":"2021","unstructured":"Carrasco I, Mart\u00ednez M, Albinyana G. Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus. Vet Dermatol. 2021;32(3):299\u2013301. doi:10.1111\/vde.12949"},{"issue":"1","key":"B58","series-title":"JFMS Open Rep","first-page":"2055116918821197","article-title":"Urticaria pigmentosa-like skin disease in a domestic shorthair cat","volume":"5","author":"Tomich LM","year":"2019","unstructured":"Tomich LM, Pieper JB. Urticaria pigmentosa-like skin disease in a domestic shorthair cat. JFMS Open Rep. 2019;5(1):2055116918821197."},{"issue":"4","key":"B59","series-title":"Vet Dermatol","first-page":"398-e113","article-title":"Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report","volume":"32","author":"Aslan J","year":"2021","unstructured":"Aslan J, Shipstone MA, Sullivan LM. Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report. Vet Dermatol. 2021;32(4):398-e113. doi:10.1111\/vde.1297634033147"},{"issue":"1","key":"B60","series-title":"BMC Vet Res","first-page":"291","article-title":"Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study","volume":"15","author":"Barrett LE","year":"2019","unstructured":"Barrett LE, Gardner HL, Barber LG, Sadowski A, London CA. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study. BMC Vet Res. 2019;15(1):291. doi:10.1186\/s12917-019-2032-4"},{"issue":"3","key":"B61","series-title":"Br J Cancer","first-page":"365","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","volume":"113","author":"Thomas SJ","year":"2015","unstructured":"Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113(3):365\u2013371. doi:10.1038\/bjc.2015.23326151455"},{"issue":"6","key":"B62","series-title":"J Vet Intern Med","first-page":"1804","article-title":"JAK1\/2 inhibitors AZD1480 and CYT387 inhibit canine B-cell lymphoma growth by increasing apoptosis and disrupting cell proliferation","volume":"31","author":"Lu Z","year":"2017","unstructured":"Lu Z, Hong CC, Jark PC, et al. JAK1\/2 inhibitors AZD1480 and CYT387 inhibit canine B-cell lymphoma growth by increasing apoptosis and disrupting cell proliferation. J Vet Intern Med. 2017;31(6):1804\u20131815. doi:10.1111\/jvim.1483728960447"},{"issue":"3","key":"B63","series-title":"J Zoo Wildl Med","first-page":"818","article-title":"Treatment success in three Andean bears (Tremarctos ornatus) with alopecia syndrome using oclacitinib maleate (APOQUEL\u00ae)","volume":"48","author":"Drake GJ","year":"2017","unstructured":"Drake GJ, Nuttall T, L\u00f3pez J, et al. Treatment success in three Andean bears (Tremarctos ornatus) with alopecia syndrome using oclacitinib maleate (APOQUEL\u00ae). J Zoo Wildl Med. 2017;48(3):818\u2013828. doi:10.1638\/2016-0239.128920784"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/261\/S1\/javma.22.12.0570.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/261\/S1\/javma.22.12.0570.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/261\/S1\/javma.22.12.0570.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:54:16Z","timestamp":1741334056000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/261\/S1\/javma.22.12.0570.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":63,"journal-issue":{"issue":"S1"},"URL":"https:\/\/doi.org\/10.2460\/javma.22.12.0570","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}